SAN DIEGO–(BUSINESS WIRE)–#arrhythmias—Vektor Medical, developer of the vMap® next-generation arrhythmia mapping technology, today announced former Philips and Biotronik medical technology leader Marlou Janssen and Yale Clinical Professor of Medicine and past American College of Cardiology (ACC) Connecticut Chapter Governor and President Dr. Craig McPherson have joined Vektor’s advisory board.
With more than two decades of experience leading medical device teams for medtech companies across the globe (including Philips, Biotronik, and St. Jude Medical), Mrs. Janssen brings strong business acumen and extensive understanding of the worldwide healthcare markets, delivering value-based customer-focused medical solutions globally. She has proven expertise in introducing growth-oriented strategies, successfully executing sales and marketing plans, and directly managing high-performing cross-functional teams within large- and medium-sized organizations. Throughout her career, she has pioneered and launched several industry-first innovations. She will support Vektor in its commercial development, growth planning, and leadership development.
“I’m thrilled to be joining Vektor’s advisory board to assist the team in the commercial roll-out of vMap. I believe Vektor’s technology is poised to disrupt the market and greatly enhance the care of individuals affected by cardiac arrhythmias. I’m incredibly impressed by what their lean team has achieved to date and look forward to supporting them in their strategic and clinical operations,” said Mrs. Janssen.
Dr. McPherson is a highly respected electrophysiologist and Clinical Professor of Medicine at Yale University. With more than four decades of experience, he joins Vektor’s clinical advisory board to share his wealth of experience and expertise with the team. He is presently the longest-serving cardiology program director in the U.S. and served as chapter president and representative to the ACC’s Board of Governors from 2020-2023. He has also served as the co-chair of the Institutional Review Board and member of the Nominating Committee and the Graduate Medical Education Committee.
“From my initial meeting with the Vektor team, it was immediately apparent to me that they have developed an exceptional technology with the potential to revolutionize the treatment of arrhythmias and significantly enhance patient outcomes,” said Dr. McPherson. “I’m excited to support Vektor in furthering their mission and leverage my expertise to increase awareness of Vektor’s groundbreaking solution.”
“We are honored to welcome Marlou Janssen and Dr. Craig McPherson to our clinical advisory board. With their exceptional medical expertise and vast experience in electrophysiology, we are confident that they will provide invaluable insights and guidance to our team,” said Rob Krummen, CEO of Vektor Medical. “Both of these exemplary leaders are acutely aware of the need for new technologies that can safely and effectively improve treatment for the millions of people suffering from arrhythmias. We are delighted they have chosen to join Vektor Medical’s effort to drastically improve cardiac care.”
vMap® is a next-generation, FDA-cleared technology that enables rapid and non-invasive mapping of arrhythmia sources for focal or fibrillation-type arrhythmias in all four chambers of the heart, with 97.3% accuracy. vMap utilizes advanced machine learning techniques and proprietary computational models to extract valuable information from a standard 12-lead ECG, providing functional insights into the location of arrhythmia sources. The goal of vMap is to improve medicine by optimizing our understanding of arrhythmias and improving ablations by accurately identifying the sources of those arrhythmias.
About Vektor Medical
San Diego-based Vektor Medical is committed to enhancing arrhythmia care for the millions of individuals affected by atrial fibrillation and other arrhythmias. Through its non-invasive cardiac arrhythmia technology, vMap, the company aims to enhance the success rate of first-pass ablation, reduce the risks associated with invasive mapping, and shorten procedure times. These advancements are expected to result in better outcomes for patients and a decrease in healthcare costs related to ablation procedures.